Here are five things to know:
1. The company will offer 750,000 shares and the selling stockholders named in the registration statement will sell 3.75 million shares.
2. The underwriter has a 30-day option to purchase up to 675,000 additional shares of common stock from the company and selling stockholders on a pro rata basis.
3. The primary portion proceeds will be used for working capital and general corporate purposes, including expanding the company’s global distribution network and purchasing inventory to support the sales efforts.
4. The proceeds may also go toward acquiring or investing in complementary products, technologies or businesses.
5. The company won’t receive any proceeds from shares of common stock sold by the selling stockholders.
6. Barclays is acting as the sole book-running manager and underwriter for the offering.
More articles on orthopedic devices:
SeaSpine completes spin off, has $47M cash
3rd spinal cord injury patient with InVivo’s Neuro-Spinal Scaffold improving: 5 key updates
Spineology introduces spine platform in the United States: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
